Impulse Control Disorder in Parkinson's Disease During Dopamine Agonist Therapy

This protocol addresses a Parkinson's disease patient who presents with impulse control disorder (ICD) while on dopamine agonist treatment — a specific clinical situation that calls for a structured, stepwise approach.

Clinical Scenario

Parkinson's disease with impulse control disorder during treatment with dopamine agonists. Gradual reduction of dopamine agonists is an effective treatment for ICDs in this setting.

Treatment Approach — Partial Overview

For patients who additionally have an indication for non-oral follow-up therapy, specific advanced options may be considered to address the impulse control disorder — the complete regimen and decision steps are in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

Gradual reduction of dopamine agonists is an effective treatment for ICDs.

For patients with an indication for non-oral follow-up therapy, Levodopa-Carbidopa Intestinal Gel (LCIG) therapy may be considered for treating ICDs.

Bilateral STN-DBS is an effective therapy for treating ICDs in patients with an indication for non-oral follow-up therapy.

DOI: 10.1186/s42466-024-00325-4

View source ↗